PUMA BIOTECHNOLOGY, INC. (PBYI) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 51.62M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 51.62M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 51.62M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 51.62M | (m) | (m) |
| 2026-03-31 | 50.90M | (m) | (m) |
| 2025-09-30 | 50.39M | (m) | (m) |
| 2025-06-30 | 50.37M | 0.00 | 0.00% |
| 2025-03-31 | 49.64M | (m) | (m) |
| 2024-09-30 | 49.09M | (m) | (m) |
| 2024-06-30 | 49.05M | (m) | (m) |
| 2024-03-31 | 48.24M | (m) | (m) |
| 2023-12-31 | 48.21M | (m) | (m) |
| 2023-09-30 | 47.57M | (m) | (m) |
| 2023-06-30 | 47.51M | (m) | (m) |
| 2023-03-31 | 46.71M | (m) | (m) |
| 2022-12-31 | 46.64M | (m) | (m) |
| 2022-09-30 | 45.64M | (m) | (m) |
| 2022-06-30 | 45.56M | (m) | (m) |
| 2022-03-31 | 44.97M | (m) | (m) |
| 2021-12-31 | 41.33M | (m) | (m) |
| 2021-09-30 | 40.89M | (m) | (m) |
| 2021-06-30 | 40.78M | (m) | (m) |
| 2021-03-31 | 40.36M | (m) | (m) |
| 2020-12-31 | 40.26M | (m) | (m) |
| 2020-09-30 | 39.76M | (m) | (m) |
| 2020-06-30 | 39.68M | (m) | (m) |
| 2020-03-31 | 39.36M | (m) | (m) |
| 2019-09-30 | 38.96M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |